{ "id": "epw5ahmpd3", "slug": "helicobacter-pylori-eradication-therapy", "title": "Helicobacter pylori eradication therapy", "updated": "2026-10-15", "topic_path": [ { "id": "life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/topics/life" }, { "id": "life.health", "label": "Human health and medicine", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health" }, { "id": "life.health.medicines", "label": "Medicines and therapeutics", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.medicines" }, { "id": "life.health.medicines.anti-infective-drugs", "label": "Anti-infective drugs and resistance", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.medicines.anti-infective-drugs" }, { "id": "life.health.medicines.anti-infective-drugs.antibacterial-drugs", "label": "Antibacterial drugs", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.medicines.anti-infective-drugs.antibacterial-drugs" } ], "geo": [ { "id": "geo.nongeo.t1946.life.health.medicines", "label": "Non-geographic · 1946 to 2000: Medicines and therapeutics", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.medicines", "path": [ { "id": "geo.nongeo", "label": "Non-geographic", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo" }, { "id": "geo.nongeo.t1946", "label": "Non-geographic · 1946 to 2000", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946" }, { "id": "geo.nongeo.t1946.life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life" }, { "id": "geo.nongeo.t1946.life.health", "label": "Human health and medicine", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health" }, { "id": "geo.nongeo.t1946.life.health.medicines", "label": "Medicines and therapeutics", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.medicines" } ] } ], "excerpt": "Helicobacter pylori eradication therapy is a combination antibiotic and acid-suppressing treatment, usually 14 days long, that cures H. pylori infection, healing ulcers and reducing gastric cancer risk.", "snippet": "Helicobacter pylori eradication therapy is a combination antibiotic and acid-suppressing treatment, usually 14 days long, that cures H. pylori infection, healing ulcers and reducing gastric cancer risk.", "node": "life.health.medicines.anti-infective-drugs.antibacterial-drugs", "markdown": "# Helicobacter pylori eradication therapy\n\nHelicobacter pylori eradication therapy is a combination antibiotic and acid-suppressing treatment regimen used in clinical medicine to eliminate H. pylori infection from the stomach. All patients with active infection confirmed by a non-serologic test should be offered treatment, because eradication is associated with peptic ulcer healing, reduced ulcer recurrence, reduced gastric cancer risk, and possible improvement of dyspepsia.[1](https://www.uptodate.com/contents/treatment-of-helicobacter-pylori-infection-in-adults) The bacterium causes more than 90% of duodenal ulcers and up to 80% of gastric ulcers, and infected patients are cured of peptic ulcer disease only when the bacteria are eliminated.[2](https://www.nobelprize.org/prizes/medicine/2005/press-release/) Roughly 44–50% of the global population is infected, exceeding 70% in some regions.[3](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1780052/full) Because no single antibiotic reliably cures the infection, current regimens combine one to three antimicrobials with a potent acid suppressant, usually a proton pump inhibitor (PPI) or a potassium-competitive acid blocker (PCAB).[1](https://www.uptodate.com/contents/treatment-of-helicobacter-pylori-infection-in-adults)\n\n| Key fact | Detail |\n|---|---|\n| Preferred first-line regimen when susceptibility is unknown | Bismuth quadruple therapy for 14 days[4](https://journals.lww.com/ajg/fulltext/2024/09000/acg_clinical_guideline__treatment_of_helicobacter.13.aspx) |\n| Definition of eradication | Absence of the bacterium 4–6 weeks after treatment; absence at the end of treatment is only \"clearance\"[5](https://gut.bmj.com/content/gutjnl/71/9/1724.full.pdf) |\n| Why 14 days | 14-day PPI triple therapy eradicated 82% vs 73% for 7 days across 45 studies[6](https://cag-acg.org/images/publications/Hp_Toronto_Consensus_2016.pdf) |\n| US resistance driving regimen choice | Clarithromycin 20–30%, levofloxacin approaching 40%, amoxicillin, tetracycline, and rifabutin all below 5%[4](https://journals.lww.com/ajg/fulltext/2024/09000/acg_clinical_guideline__treatment_of_helicobacter.13.aspx) |\n| Best-documented new regimen | Vonoprazan triple therapy, 92.6% vs 75.9% for lansoprazole triple therapy in a Japanese phase III trial[7](https://gut.bmj.com/content/65/9/1439) |\n| Head-to-head benchmark | 10-day bismuth quadruple therapy 90.4% vs 83.7% for 14-day triple therapy (1620-patient Taiwanese trial)[8](https://pubmed.ncbi.nlm.nih.gov/27769562/) |\n| Recognition of the discovery | 2005 Nobel Prize to Barry J. Marshall and J. Robin Warren[2](https://www.nobelprize.org/prizes/medicine/2005/press-release/) |\n\n## How it works\n\nAcid suppression is not an end in itself; it makes the antibiotics work. Raising intragastric pH above 6 promotes active replication of H. pylori, which increases susceptibility to bactericidal antibiotics, and stabilizes acid-labile drugs such as clarithromycin and amoxicillin, increasing their intragastric concentration.[4](https://journals.lww.com/ajg/fulltext/2024/09000/acg_clinical_guideline__treatment_of_helicobacter.13.aspx) PPIs achieve this by irreversibly binding and inhibiting H⁺,K⁺-ATPase on parietal cells, and are mainly metabolized by CYP2C19.[9](https://pubmed.ncbi.nlm.nih.gov/36660052/) PCABs such as vonoprazan bind the same proton pump through a different mechanism, giving a more rapid, robust, and prolonged antisecretory effect.[4](https://journals.lww.com/ajg/fulltext/2024/09000/acg_clinical_guideline__treatment_of_helicobacter.13.aspx)\n\nMultiple antibiotics are combined to defeat resistance. Concomitant therapy pairs clarithromycin with metronidazole on the logic that dual resistance should be rare: with US metronidazole resistance of 20–40% and clarithromycin resistance near 20%, expected dual resistance is about 0.4 × 0.2 = 8%, because each antibiotic kills strains resistant to the other.[10](https://www.ccjm.org/content/84/4/310) Longer treatment also helps kill organisms persisting in different niches, from gastric mucus to inside epithelial cells.[10](https://www.ccjm.org/content/84/4/310) The accepted performance standard is a cure rate of at least 90%, and an optimized regimen is one achieving at least 95% cure in patients with susceptible organisms.[11](https://pmc.ncbi.nlm.nih.gov/articles/PMC3830667/)\n\n## How it is done\n\nOptimized [bismuth quadruple therapy](https://www.edgepedia.org/bismuth-quadruple-therapy) (BQT) uses bismuth 300 mg four times daily at least, metronidazole 1.5–2 g daily in 3 or 4 doses, tetracycline 500 mg four times daily, and a twice-daily standard-dose PPI for 10 to, preferably, 14 days.[4](https://journals.lww.com/ajg/fulltext/2024/09000/acg_clinical_guideline__treatment_of_helicobacter.13.aspx) Other standard doses are amoxicillin 1000 mg twice daily, clarithromycin 500 mg twice daily, levofloxacin 500 mg once daily, and rifabutin 150 mg twice daily.[6](https://cag-acg.org/images/publications/Hp_Toronto_Consensus_2016.pdf) Consensus groups strongly recommend that all eradication regimens run 14 days.[6](https://cag-acg.org/images/publications/Hp_Toronto_Consensus_2016.pdf)\n\nCure is confirmed with a urea breath test or stool antigen test at least 4 weeks after therapy, with antibiotics, bismuth, and PPIs withheld for at least 2 weeks beforehand.[10](https://www.ccjm.org/content/84/4/310) Testing earlier than 4–6 weeks after treatment measures clearance, not eradication.[5](https://gut.bmj.com/content/gutjnl/71/9/1724.full.pdf)\n\n## Origin\n\nThe successful culture of patient 35 followed a lucky accident in which plates were left in the incubator over the Easter weekend.[12](https://www.ncbi.nlm.nih.gov/books/NBK2432/) Barry J. Marshall and colleagues then fulfilled [Koch's postulates](https://www.edgepedia.org/kochs-postulates) (criteria proving a microbe causes a disease) by self-experimentation, reported in the Medical Journal of Australia in 1985.[13](https://doi.org/10.5694/j.1326-5377.1985.tb113443.x) Rauws and Tytgat showed in [The Lancet](https://www.edgepedia.org/the-lancet) in 1990 that duodenal ulcer could be cured by eradicating the bacterium.[14](https://doi.org/10.1016/0140-6736%2890%2991301-p) A 1995 New England Journal of Medicine trial of 100 patients then showed that one week of bismuth subcitrate, tetracycline, and metronidazole eradicated H. pylori in 91.1% versus 12.5% with four weeks of omeprazole, and that antibacterial therapy without acid suppression healed ulcers as well as omeprazole.[15](https://www.nejm.org/doi/full/10.1056/NEJM199501193320302) A 1996 review of 237 treatment arms found bismuth triple therapy achieved 78–89% eradication and quadruple therapy a mean of 96%.[16](https://onlinelibrary.wiley.com/doi/10.1111/j.1523-5378.1996.tb00003.x) The 2005 [Nobel Prize in Physiology or Medicine](https://www.edgepedia.org/nobel-prize-in-physiology-or-medicine) went jointly to Marshall and Warren.[2](https://www.nobelprize.org/prizes/medicine/2005/press-release/)\n\n## Variants\n\n**Sequential therapy** alternates drugs rather than giving them together: a PPI with amoxicillin 1 g twice daily for 5 days, then PPI, clarithromycin 500 mg, and metronidazole 500 mg twice daily for 5 more days, a regimen reported by Zullo and colleagues in 2003.[17](https://doi.org/10.1046/j.1365-2036.2003.01461.x) In an Italian trial it eradicated 89% versus 77% for 10-day triple therapy, and 89% versus 29% in clarithromycin-resistant strains.[18](https://www.acpjournals.org/doi/10.7326/0003-4819-146-8-200704170-00006) **Hybrid therapy**, reported by Hsu and colleagues in 2011, extends the dual phase: PPI plus amoxicillin for 7 days, then quadruple therapy with clarithromycin and metronidazole added for the final 7 days.[19](https://doi.org/10.1111/j.1523-5378.2011.00828.x) A meta-analysis of 10 studies found mean ITT eradication of 86% for hybrid therapy, with no significant difference from concomitant or sequential therapy.[20](https://link.springer.com/article/10.1186/s12941-023-00582-2) **Concomitant therapy** gives PPI, amoxicillin, clarithromycin, and metronidazole together throughout, achieving about 90% versus 78% for triple therapy in meta-analysis.[21](https://pmc.ncbi.nlm.nih.gov/articles/PMC5505131/) In a 1620-patient Taiwanese trial, 10-day BQT (90.4%) was superior to 14-day triple therapy, while 10-day concomitant therapy (85.9%) was not.[8](https://pubmed.ncbi.nlm.nih.gov/27769562/)\n\n**PCAB-based regimens** are the newest variant. Vonoprazan triple therapy achieved 92.6% versus 75.9% for lansoprazole triple therapy, and 82.0% versus 40.0% in clarithromycin-resistant strains.[7](https://gut.bmj.com/content/65/9/1439) Two vonoprazan products, Voquezna DualPak and Voquezna TriplePak, were FDA-approved in 2022.[4](https://journals.lww.com/ajg/fulltext/2024/09000/acg_clinical_guideline__treatment_of_helicobacter.13.aspx) **Rifabutin triple therapy** is available as the fixed-dose product Talicia (omeprazole 120 mg, rifabutin 150 mg, amoxicillin 3 g total daily).[4](https://journals.lww.com/ajg/fulltext/2024/09000/acg_clinical_guideline__treatment_of_helicobacter.13.aspx) **Rifasutenizol**, the first novel antimicrobial agent specifically developed for H. pylori, achieved 92.0% versus 87.9% for bismuth plus clarithromycin-based triple therapy in the Chinese EVEREST-HP phase 3 trial, meeting noninferiority.[22](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2825%2900438-4/abstract)\n\n## Applications\n\nEradication is offered to every patient with confirmed active infection, and delivers ulcer healing, lower recurrence, reduced gastric cancer risk, and possible dyspepsia relief.[1](https://www.uptodate.com/contents/treatment-of-helicobacter-pylori-infection-in-adults) MALT lymphomas may regress when the bacterium is eradicated by antibiotics.[2](https://www.nobelprize.org/prizes/medicine/2005/press-release/) The 1995 trial quantified the ulcer benefit: recurrent gastric ulcers at one year occurred in 4.5% of antibacterial-treated patients versus 52.2% of omeprazole-treated patients.[15](https://www.nejm.org/doi/full/10.1056/NEJM199501193320302) In experienced centers, eradication after up to three judiciously chosen treatments should approach 98%.[23](https://www.worldgastroenterology.org/UserFiles/file/guidelines/helicobacter-pylori-english-2021.pdf)\n\n## Limitations and alternatives\n\n**Resistance is the main limitation.** Pooled data from 20 studies showed [standard triple therapy](https://www.edgepedia.org/standard-triple-therapy) eradicated 88% of clarithromycin-susceptible but only 18% of clarithromycin-resistant strains.[21](https://pmc.ncbi.nlm.nih.gov/articles/PMC5505131/) Seven-day triple therapy falls below 90% success when clarithromycin resistance exceeds 5%, and 14-day therapy when it exceeds 15%; empiric triple therapy should be abandoned where clarithromycin resistance is 15–20% or greater.[11](https://pmc.ncbi.nlm.nih.gov/articles/PMC3830667/) • [23](https://www.worldgastroenterology.org/UserFiles/file/guidelines/helicobacter-pylori-english-2021.pdf) In Asia-Pacific populations, primary resistance has been reported at 30% for clarithromycin, 35% for levofloxacin, and 61% for metronidazole.[24](https://www.mdpi.com/2076-2607/13/3/519) Susceptibility-guided therapy improves eradication versus empirical triple therapy (RR 1.20), though empirical bismuth quadruple therapy outperformed tailored therapy in the same meta-analysis (RR 0.93).[25](https://link.springer.com/article/10.1186/s12879-025-12289-0)\n\n**Side effects and adherence** constrain every regimen. In the Liou trial, adverse events affected 67% of BQT, 58% of concomitant, and 47% of triple therapy patients.[8](https://pubmed.ncbi.nlm.nih.gov/27769562/) BQT causes abdominal pain, nausea, and vomiting that often result in poor adherence, and carries a pill burden of 14 pills per day versus 8 for concomitant therapy.[10](https://www.ccjm.org/content/84/4/310) • [26](https://www.mdpi.com/2077-0383/12/9/3258) [Levofloxacin](https://www.edgepedia.org/levofloxacin) carries rare risks of tendinitis or myositis, and rifabutin-based salvage is generally less effective, with neutropenia risk up to 1%.[23](https://www.worldgastroenterology.org/UserFiles/file/guidelines/helicobacter-pylori-english-2021.pdf)\n\n**Salvage therapy** follows failure of first-line treatment. The 2024 ACG guideline prefers optimized BQT for 14 days if not previously used, then rifabutin triple therapy; clarithromycin- or levofloxacin-containing salvage should be used only with confirmed susceptibility.[4](https://journals.lww.com/ajg/fulltext/2024/09000/acg_clinical_guideline__treatment_of_helicobacter.13.aspx) Acid suppression alone is not an alternative: omeprazole eradicated the bacterium in only 12.5% of patients and left more than half with recurrent ulcers at one year.[15](https://www.nejm.org/doi/full/10.1056/NEJM199501193320302)\n\n## References\n\n1. [Treatment of Helicobacter pylori infection in adults (UpToDate, updated Mar 2026)](https://www.uptodate.com/contents/treatment-of-helicobacter-pylori-infection-in-adults)\n2. [Press release: The Nobel Prize in Physiology or Medicine 2005](https://www.nobelprize.org/prizes/medicine/2005/press-release/)\n3. [Efficacy and safety of antibiotic regimens for H. pylori eradication: systematic review and meta-analysis (Frontiers in Medicine, 2026)](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1780052/full)\n4. [ACG Clinical Guideline: Treatment of Helicobacter pylori Infection (2024)](https://journals.lww.com/ajg/fulltext/2024/09000/acg_clinical_guideline__treatment_of_helicobacter.13.aspx)\n5. [Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report](https://gut.bmj.com/content/gutjnl/71/9/1724.full.pdf)\n6. [The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults (2016)](https://cag-acg.org/images/publications/Hp_Toronto_Consensus_2016.pdf)\n7. [Vonoprazan as a component of first-line and second-line triple therapy for H. pylori eradication: phase III RCT (Gut)](https://gut.bmj.com/content/65/9/1439)\n8. [Concomitant, bismuth quadruple, and 14-day triple therapy in first-line treatment of H. pylori: multicentre open-label RCT (Liou et al.)](https://pubmed.ncbi.nlm.nih.gov/27769562/)\n9. [Management of Helicobacter pylori infection (2023 consensus review)](https://pubmed.ncbi.nlm.nih.gov/36660052/)\n10. [Treating Helicobacter pylori effectively while minimizing misuse of antibiotics (Cleveland Clinic Journal of Medicine, 2017)](https://www.ccjm.org/content/84/4/310)\n11. [Rational Helicobacter pylori therapy: evidence based medicine rather than medicine based evidence (Graham)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3830667/)\n12. [One Hundred Years of Discovery and Rediscovery of Helicobacter pylori and Its Association with Peptic Ulcer Disease (NCBI Bookshelf)](https://www.ncbi.nlm.nih.gov/books/NBK2432/)\n13. [Barry J. Marshall and colleagues (1985). Attempt to fulfil Koch's postulates for pyloric Campylobacter. The Medical Journal of Australia.](https://doi.org/10.5694/j.1326-5377.1985.tb113443.x)\n14. [Cure of duodenal ulcer associated with eradication of Helicobacter pylori (The Lancet, 1990)](https://doi.org/10.1016/0140-6736%2890%2991301-p)\n15. [Antibacterial Treatment of Gastric Ulcers Associated with Helicobacter pylori (NEJM, 1995)](https://www.nejm.org/doi/full/10.1056/NEJM199501193320302)\n16. [Treatment of Helicobacter pylori Infection: A Review of the World Literature (Helicobacter, 1996)](https://onlinelibrary.wiley.com/doi/10.1111/j.1523-5378.1996.tb00003.x)\n17. [A. Zullo and colleagues (2003). High eradication rates of Helicobacter pylori with a new sequential treatment. Alimentary Pharmacology & Therapeutics.](https://doi.org/10.1046/j.1365-2036.2003.01461.x)\n18. [Sequential Therapy versus Standard Triple-Drug Therapy for H. pylori Eradication: A Randomized Trial (Vaira et al., Annals 2007)](https://www.acpjournals.org/doi/10.7326/0003-4819-146-8-200704170-00006)\n19. [Ping‐I. Hsu and colleagues (2011). Modified Sequential Helicobacter pylori Therapy: Proton Pump Inhibitor and Amoxicillin for 14 Days with Clarithromycin and Metronidazole added as a Quadruple (Hybrid) Therapy for the Final 7 Days. Helicobacter.](https://doi.org/10.1111/j.1523-5378.2011.00828.x)\n20. [Is hybrid therapy more efficient in the eradication of H. pylori? A systematic review and meta-analysis (Ann Clin Microbiol Antimicrob, 2023)](https://link.springer.com/article/10.1186/s12941-023-00582-2)\n21. [Update on the first-line treatment for Helicobacter pylori infection – a continuing challenge from an old enemy (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5505131/)\n22. [abstract (thelancet.com)](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2825%2900438-4/abstract)\n23. [WGO Global Guideline: Helicobacter pylori (2021)](https://www.worldgastroenterology.org/UserFiles/file/guidelines/helicobacter-pylori-english-2021.pdf)\n24. [Efficacy and Safety of Modified Bismuth Quadruple Therapy for First-Line H. pylori Eradication: meta-analysis of RCTs (Microorganisms)](https://www.mdpi.com/2076-2607/13/3/519)\n25. [Empirical therapy versus tailored therapy for H. pylori infection? A systematic review (BMC Infectious Diseases, 2025)](https://link.springer.com/article/10.1186/s12879-025-12289-0)\n26. [Standard Bismuth Quadruple Therapy versus Concomitant Therapy for First-Line H. pylori Treatment: systematic review and meta-analysis of RCTs (J Clin Med)](https://www.mdpi.com/2077-0383/12/9/3258)\n\n---\n*Topic: Encyclopedia › Life and health › Human health and medicine › Medicines and therapeutics › Anti-infective drugs and resistance › Antibacterial drugs*\n\n*Initially written Sep 29, 2026 · Edited: Oct 15, 2026*\n\n*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*\n\nLicense: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license\n", "same_as": [], "url": "https://www.edgepedia.org/helicobacter-pylori-eradication-therapy", "markdown_url": "https://www.edgepedia.org/helicobacter-pylori-eradication-therapy.md", "license": { "name": "Edgepedia Community License 1.0", "url": "https://www.edgepedia.org/edgepedia/license", "summary": "Free with credit, commercial use included. AI training is open to everyone. For other uses, organizations over USD 100M in revenue or 100M monthly users license separately.", "spdx": "LicenseRef-Edgepedia-Community-1.0" }, "credit": "\"Helicobacter pylori eradication therapy\", Edgepedia (EdgeChat), https://www.edgepedia.org/helicobacter-pylori-eradication-therapy. Edgepedia Community License 1.0.", "credit_md": "\"[Helicobacter pylori eradication therapy](https://www.edgepedia.org/helicobacter-pylori-eradication-therapy)\", Edgepedia (EdgeChat), [https://www.edgepedia.org/helicobacter-pylori-eradication-therapy](https://www.edgepedia.org/helicobacter-pylori-eradication-therapy). [Edgepedia Community License 1.0](https://www.edgepedia.org/edgepedia/license).", "credit_html": "\"Helicobacter pylori eradication therapy\", Edgepedia (EdgeChat), https://www.edgepedia.org/helicobacter-pylori-eradication-therapy. Edgepedia Community License 1.0.", "speakable": "Helicobacter pylori eradication therapy is a combination antibiotic and acid-suppressing treatment, usually 14 days long, that cures H. pylori infection, healing ulcers and reducing gastric cancer risk." }